Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome

Inclusion Criteria: * Clinical diagnosis of FXTAS * Serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and EKG are within normal limits Exclusion Criteria: * Legal incapacity or limited legal capacity * Presence of severe renal disease (BUN 50% greater than normal or creatinine clearance \<60 mL/min) or hepatic disease. * Abnormal creatine kinase and/or platelet count in the past 6 months (as determined by lab reports obtained from primary care physicians or conducted at baseline). * Women of childbearing potential who are pregnant at the time of screening or who will not use adequate protection during participation of the study. * Allergy/sensitivity to the drug of its formulations. * Concurrent participation in another clinical study. * Active substance use or dependence. * Serious illness (requiring systematic treatment/or hospitalization) until the subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 60 days prior to study entry. * Inability or unwillingness of the subject or legal guardian/representative to give written informed consent.